Vanguard Portfolio Management’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
Other funds holding PCRX
Vanguard Portfolio Management's PCRX Position: Q3 2026 in Review
Vanguard Portfolio Management reduced its Pacira BioSciences (PCRX) stake by 1.4% in Q3 2026, selling an estimated $860K and leaving 2,372,291 shares worth $59.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1646.
Vanguard Portfolio Management first reported a position in PCRX in Q1 2026 and has held it in 3 quarters since. The position peaked at $61M in Q2 2026. 258 funds tracked by Wall St. Rank hold PCRX as of Q3 2026.
- Vanguard Portfolio Management held 2,372,291 shares of Pacira BioSciences worth $59.4M as of Q3 2026.
- Vanguard Portfolio Management sold 33,947 Pacira BioSciences shares in Q3 2026, an estimated $860K.
- Pacira BioSciences made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q3 2026, its #1646 holding.
- Vanguard Portfolio Management first reported a position in Pacira BioSciences in Q1 2026 and has held it in 3 quarters since.
- Vanguard Portfolio Management's Pacira BioSciences position peaked at $61M in Q2 2026.
- 258 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2026.
Based on Vanguard Portfolio Management's 13F filing for Q3 2026, filed 13 Nov 2026.